Home » Stocks » ANNX

Annexon Biosciences, Inc. (ANNX)

Stock Price: $21.78 USD 0.26 (1.21%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $23.10 +1.32 (6.06%) Apr 20, 5:20 PM
Market Cap 840.99M
Revenue (ttm) n/a
Net Income (ttm) -70.34M
Shares Out 38.16M
EPS (ttm) -4.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $21.78
Previous Close $21.52
Change ($) 0.26
Change (%) 1.21%
Day's Open 21.36
Day's Range 21.36 - 22.34
Day's Volume 68,440
52-Week Range 15.33 - 38.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for pa...

3 weeks ago - GlobeNewsWire

Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) ...

1 month ago - Benzinga

SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with c...

1 month ago - GlobeNewsWire

Thomas G. Wiggans appointed Chairman Thomas G. Wiggans appointed Chairman

2 months ago - GlobeNewsWire

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...

Other stocks mentioned: ASA, BME, BMEZ, BST, BSTZ, GMAB, GNMSF ...
2 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...

3 months ago - GlobeNewsWire

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, engages in developing therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its products in pipelines are focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. Its products include ANX005 (IV), which is in Phase III stage with guillain-barré syndrome indication, as well as in Phase II stage with warm autoimmune hemolytic anemia, huntington's disease, and amyotrophic lateral sclerosis indications; ANX007 (... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ANNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price forecast is 37.00, which is an increase of 69.88% from the latest price.

Price Target
$37.00
(69.88% upside)
Analyst Consensus: Strong Buy